2022
DOI: 10.1097/mpa.0000000000002016
|View full text |Cite
|
Sign up to set email alerts
|

Coefficient of Fat Absorption to Measure the Efficacy of Pancreatic Enzyme Replacement Therapy in People With Cystic Fibrosis

Abstract: Objectives: We sought data on the validity, reliability, responsiveness, and feasibility of the coefficient of fat absorption (CFA) as a measure of pancreatic enzyme replacement therapy (PERT) efficacy in people with cystic fibrosis (pwCF) and reviewed the literature for alternative measures. Methods:We searched PubMed for the Medical Subject Heading cystic fibrosis and the key words cystic fibrosis, fat absorption, CFA, and fecal fat imbalance; historical articles; and citations in bibliographies. Results:The… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
16
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 13 publications
(16 citation statements)
references
References 76 publications
0
16
0
Order By: Relevance
“…These regimens have high risks of gastrointestinal toxicities, including nausea, vomiting, and diarrhea, which often T A B L E 1 Available assessments to diagnose EPI, including the rationale and limitations for use. 8 result in impaired oral intake in the absence of aggressive symptom control and targeted nutrition therapies. 23 It is critical to maintain nutrition intake during neoadjuvant therapy because the ultimate goal is to successfully undergo surgical resection, and malnutrition may present a barrier to surgery.…”
Section: Cancer Staging and Treatmentsmentioning
confidence: 99%
See 2 more Smart Citations
“…These regimens have high risks of gastrointestinal toxicities, including nausea, vomiting, and diarrhea, which often T A B L E 1 Available assessments to diagnose EPI, including the rationale and limitations for use. 8 result in impaired oral intake in the absence of aggressive symptom control and targeted nutrition therapies. 23 It is critical to maintain nutrition intake during neoadjuvant therapy because the ultimate goal is to successfully undergo surgical resection, and malnutrition may present a barrier to surgery.…”
Section: Cancer Staging and Treatmentsmentioning
confidence: 99%
“…20,52,53 Alternatively, PERT may be dosed according to g of dietary fat intake (500-4000 UL per gram of dietary fat) or body weight (500-2500 UL per kilogram of body weight per meal). 8,54 However, it should be noted that these adjusted dosing strategies have primarily been studied and employed in children with cystic fibrosis. Nevertheless, the concept of using an individualized approach is reasonable because dietary patterns vary widely between individuals and may change over time (eg, during chemotherapy treatments).…”
Section: Pancreas Enzyme Replacement Therapymentioning
confidence: 99%
See 1 more Smart Citation
“…Diagnostic tests for fat malabsorption are primarily based on those in the cystic fibrosis (CF) and chronic pancreatitis literature for evaluation of pancreatic enzyme insufficiency. 55 As fat malabsorption, by definition, results in increased fecal fat content, measurement of fecal fat is often the initial step. The Sudan stain is an inexpensive, easy, and reasonably sensitive qualitative test of fat malabsorption (Table 4).…”
Section: Diagnosis and Evaluationmentioning
confidence: 99%
“…Fat malabsorption may be suspected clinically in the SBS patient with steatorrhea, weight loss, failure to thrive, fat‐soluble vitamin deficiencies, or EFAD. Diagnostic tests for fat malabsorption are primarily based on those in the cystic fibrosis (CF) and chronic pancreatitis literature for evaluation of pancreatic enzyme insufficiency 55 . As fat malabsorption, by definition, results in increased fecal fat content, measurement of fecal fat is often the initial step.…”
Section: Diagnosis and Evaluationmentioning
confidence: 99%